comprehensive -WSS

comprehensive

author：focus 2025-09-29 19:06:22 - browse：663

Two people in protective equipment work in a lab. — JUAN MABROMATA/AFP via Getty Images

Biosimilars are no longer a new and untested class of medicines. Today, they provide critical treatment options across multiple therapeutic areas. Since the Biologics Price Competition and Innovation Act of 2009 created a regulatory pathway for biosimilar medicine review in the U.S., 37 biosimilars have come to market offering the potential to increase patient choice and cost savings. And according to the 2023 analysis from IQVIA, biosimilars are expected to generate $181 billion in savings for the U.S. health care system over the next five years.

This progress is due, in part, to thoughtfully considered, scientifically robust regulatory standards, which have instilled confidence among health care providers and patients while protecting safety. As a former associate director of therapeutic biologics at the Food and Drug Administration, I had the privilege of helping create and lead implementation of the regulatory framework for biosimilars. The FDA took great care to apply appropriate scientific rigor to the development and approval standards. While I have since moved to Amgen, my goals have remained focused on biosimilar product quality and efficacy, patient safety, and prescriber confidence.

More than a decade later, collective efforts by biosimilar manufacturers and the FDA are paying off.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： New details revealed about Purdue's marketing of OxyContin

focus

WSS

American woman kidnapped in Mexico freed after 8 months in captivity: FBI

Cancer drug shortages' outsize impact on ovarian cancer patients

Patient advocates sound warning on FDA proposal on salt intake

New details revealed about Purdue's marketing of OxyContin

Lung cancer is America's deadliest cancer. Yet so few get screened

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

knowledge

comprehensive

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Baltimore teen accused of firing into crowd during block party mass shooting

23andMe had bad news about my health. I wish a person had delivered it

Involuntary treatment for addiction doesn't work

The high cost of giving birth even with insurance

Trump cancels press conference intended to dispute Georgia election interference charges

The cancer drug shortage isn’t new — and neither are the solutions

As Maui death toll rises, number of missing remains unclear

Bright Health sells Medicare Advantage business to Molina

New definition of a human embryo proposed amid rapid advances

leisure time

Woman gored by Bison at Yellowstone

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

Congress must give Medicare recipients genetic counseling access

Argenx drug significantly slows progression of nerve disorder

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

focus

Wikipedia

knowledge

knowledge